Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Lung Neoplasms 3644Carcinoma, Non-Small-Cell Lung 3585Small Cell Lung Carcinoma 576Breast Neoplasms 419Neoplasms 299Adenocarcinoma of Lung 249Colorectal Neoplasms 222Melanoma 201Mesothelioma, Malignant 183Pancreatic Neoplasms 179Prostatic Neoplasms 178Brain Neoplasms 178Head and Neck Neoplasms 173Neoplasm Metastasis 167Ovarian Neoplasms 153Esophageal Neoplasms 152Mesothelioma 145Colonic Neoplasms 140Stomach Neoplasms 139NSCLC 115Pleural Effusion, Malignant 114Carcinoma, Renal Cell 109Urinary Bladder Neoplasms 105Disease 96Sarcoma 85Uterine Cervical Neoplasms 82Thymoma 79Liver Neoplasms 77Motor Activity 75Squamous Cell Carcinoma of Head and Neck 72

Interventions

ensartinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × ALK-positive Advanced NSCLC × Thoracic × Clear all
NCT06785584 2025-01-21

Efficacy and Safety of Ensartinib in Neoadjuvant Therapy for Stage IIA - IIIB (Operable or Potentially Operable) ALK-Positive Lung Adenocarcinoma :A Multicenter, Real-World Clinical Study

Fujian Medical University Union Hospital

Phase 4 Not yet recruiting
30 enrolled
Thoracic

ALK-positive Advanced NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡